Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Brand Name :
Rebif, avonex, rebif rebidose
Synonyms :
Interferon beta-1a
Class :
interferons
Dosage Forms & Strengths
Prefilled intramuscular syringe
30mcg/0.5ml
Prefilled intramuscular autoinjector pen
30mcg/5ml
Prefilled subcutaneous syringe titration pack
8.8mcg/0.2ml
22mcg/0.5ml
Powder for injection
30mcg/vial
Prefilled subcutaneous syringe
22mcg/0.5ml
44mcg/0.5ml
Prefilled subcutaneous autoinjector
8.8mcg/syringe
22mcg/syringe
44mcg/syringe
Rebif 22mcg
Weeks 1-2: 4.4 mcg subcutaneous thrice a week
Weeks 3-4: 11 mcg subcutaneous thrice a week
Over Week 5: 22 mcg subcutaneous thrice a week
Rebif 44mcg
Weeks 1-2: 8.8 mcg subcutaneous thrice a week
Weeks 3-4: 22 mcg subcutaneous thrice a week
Over Week 5: 44 mcg subcutaneous thrice a week
Avonex
30mcg intramuscular every week
Dosage Forms & Strengths
Prefilled intramuscular syringe
30mcg/0.5ml
Prefilled intramuscular autoinjector pen
30mcg/5ml
Prefilled subcutaneous syringe titration pack
8.8mcg/0.2ml
22mcg/0.5ml
Powder for injection
30mcg/vial
Prefilled subcutaneous syringe
22mcg/0.5ml
44mcg/0.5ml
Prefilled subcutaneous autoinjector
8.8mcg/syringe
22mcg/syringe
44mcg/syringe
Avonex
30mcg intramuscular every week
Rebif 22mcg
Weeks 1-2: 4.4 mcg subcutaneous thrice a week
Weeks 3-4: 11 mcg subcutaneous thrice a week
Over Week 5: 22 mcg subcutaneous thrice a week
Rebif 44mcg
Weeks 1-2: 8.8 mcg subcutaneous thrice a week
Weeks 3-4: 22 mcg subcutaneous thrice a week
Over Week 5: 44 mcg subcutaneous thrice a week
may increase the toxic effect
may increase the toxic effect
may increase the toxic effect
Frequency defined:
>10%
Headache
Muscle ache
Urinary tract infection
Fever
Diarrhea
Infection
Injection site reaction
Flu-like syndrome
Nausea
Pain
Asthenia
Dizziness
Dyspepsia
1-10%
Anemia
Chest pain
Abdominal pain
<1%
Aggravation of seizure disorders
Post-marketing reports
Hemolytic anemia
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: Interferon beta-1a
Pronounced: [ in-ter-FEAR-on-BAY-ta ]
Why do we use Interferon beta-1a?
Interferon beta-1a is a medication used to treat relapsing forms of multiple sclerosis (MS). It is a protein called a cytokine produced naturally by the body to help fight viral infections and other diseases. Interferon beta-1a modifies the immune system’s response to the body’s tissues, which can help reduce inflammation and damage to the central nervous system. It is usually given as an injection under the skin or into a muscle and is typically used with other MS medications.